NCI Says Long-Awaited Long Island Breast Cancer Study Now Underway

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 5 No 8
Volume 5
Issue 8

BETHESDA, Md--The Long Island Breast Cancer Study Project, ordered by Congress in 1993, is now underway under the auspices of the NCI and the National Institute of Environmental Health Sciences. The study will attempt to determine whether pollutants (pesticides and other chemical irritants) are linked to the area's excessive breast cancer rates.

BETHESDA, Md--The Long Island Breast Cancer Study Project, orderedby Congress in 1993, is now underway under the auspices of theNCI and the National Institute of Environmental Health Sciences.The study will attempt to determine whether pollutants (pesticidesand other chemical irritants) are linked to the area's excessivebreast cancer rates.

During, the 4-year study, being conducted by researchers fromColumbia University School of Public Health, 33 Long Island hospitalswill provide the names of newly diagnosed breast cancer patientswhom the researchers will invite to join the study. Blood andurine samples will be taken prior to treatment, along with a familyand medical history. The researchers will collect dust, water,and soil samples from the homes of 325 participants. Planned enrollmentis 1,600 patients plus 1,600 controls, with results expected by1999.

Recent Videos
Heather Zinkin, MD, states that reflexology improved pain from chemotherapy-induced neuropathy in patients undergoing radiotherapy for breast cancer.
Study findings reveal that patients with breast cancer reported overall improvement in their experience when receiving reflexology plus radiotherapy.
Patients undergoing radiotherapy for breast cancer were offered 15-minute nurse-led reflexology sessions to increase energy and reduce stress and pain.
Whole or accelerated partial breast ultra-hypofractionated radiation in older patients with early breast cancer may reduce recurrence with low toxicity.
Ultra-hypofractionated radiation in those 65 years or older with early breast cancer yielded no ipsilateral recurrence after a 10-month follow-up.
The unclear role of hypofractionated radiation in older patients with early breast cancer in prior trials incentivized research for this group.
Patients with HR-positive, HER2-positive breast cancer and high-risk features may derive benefit from ovarian function suppression plus endocrine therapy.
Paolo Tarantino, MD discusses updated breast cancer trial findings presented at ESMO 2024 supporting the use of agents such as T-DXd and ribociclib.
Paolo Tarantino, MD, discusses the potential utility of agents such as datopotamab deruxtecan and enfortumab vedotin in patients with breast cancer.
Paolo Tarantino, MD, highlights strategies related to screening and multidisciplinary collaboration for managing ILD in patients who receive T-DXd.